A year after the serious adverse reactions that occurred in the first-in-man clinical trials of TGN1412, the European Medicines Agency’s Committee for Medicinal Products for Human Use, adopted a draft guideline on requirements for first-in-man clinic
With the emergence of electronic lab notebooks, Agilent Technologies's Dr. Alain Meller believes that it is time for pharma visionaries to recognise the potential benefit of building a knowledge base for all experimental information
How pharma companies, biotechs and CROs can improve their clinical outsourcing processes in Russia
Written by Bogdan Nietubyc of Hesperion Ltd.